Augustin Ferrant
About
In The Last Decade
Augustin Ferrant
219 papers receiving 10.6k citations
Hit Papers
Peers
Comparison fields: 5 of 134
- Hematology 6.5k
- Oncology 3.1k
- Molecular Biology 2.5k
- Genetics 2.3k
- Immunology 1.8k
Countries citing papers authored by Augustin Ferrant
This map shows the geographic impact of Augustin Ferrant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Augustin Ferrant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Augustin Ferrant more than expected).
Fields of papers citing papers by Augustin Ferrant
This network shows the impact of papers produced by Augustin Ferrant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Augustin Ferrant. The network helps show where Augustin Ferrant may publish in the future.
Co-authorship network of co-authors of Augustin Ferrant
This figure shows the co-authorship network connecting the top 25 collaborators of Augustin Ferrant. A scholar is included among the top collaborators of Augustin Ferrant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Augustin Ferrant. Augustin Ferrant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 345 | |
| 2 | Cytogenetic remissions in high-risk myelodysplastic syndrome: Results in 124 patients treated with low-dose 5-aza-2 '-deoxycytidine (Decitabine), a DNA methylation inhibitor. | 3 |
| 3 | Peripheral blood stem cells contamination in diffuse large cell (DLCL) and mantle cell (MCL) lymphomas: A quantitative comparison. | 0 |
| 4 | Spinal bone marrow magnetic resonance imaging (MRI) in stage III multiple myeloma (MM): Correlation with clinical, laboratory and histologic findings, with initial response to treatment and with patient survival. | 1 |
| 5 | 3 | |
| 6 | 56 | |
| 7 | Magnetic resonance (MR) imaging of the bone marrow to assess the risk of disease progression in patients with stage I multiple myeloma | 1 |
| 8 | Magnetic resonance (MR) imaging of the bone marrow to assess the risk of disease progression in patients with monoclonal gammapathy of undetermined significance (MGUS) | 1 |
| 9 | Trisomy 13 in myeloid malignancies: Clinical, morphologic and immunologic correlations and characterization by combined immunophenotyping and interphase fluorescence in situ hybridization (FISH). | 2 |
| 10 | Sequential quantitative magnetic resonance imaging of the bone marrow to assess treatment response in patients with acute leukemia | 1 |
| 11 | Ex-vivo Expansion of Normal Human Bone-marrow Cd34+dr(low) Cells in Liquid Culture | 1 |
| 12 | Detection of residual disease by immunostaining of bone marrow trephines (BMT) after 2-chlorodeoxyadenosine (CDA) in previously untreated chronic lymphocytic leukemia (CLL). | 1 |
| 13 | Cyclosporine-a (cy A) Has Only Marginal Antileukemic Activity in Refractory Chronic Lymphocytic-leukemia (cll) | 1 |
| 14 | 2-chlorodeoxyadenosine (cda) for Previously Untreated Chronic Lymphocytic-leukemia (cll) | 3 |
| 15 | 2-chloro-deoxyadenosine With Or Without Daunorubicin for Relapsing Or Refractory Acute Myeloblastic-leukemia | 1 |
| 16 | 2-chlorodeoxyadenosine Therapy in Non-hodgkins-lymphoma | 2 |
| 17 | A Single Course of 2-chloro-deoxyadenosine (2-cda) Does Not Eradicate Leukemic-cells in Hairy-cell Leukemia (hcl) Patients Achieving Complete Remission | 3 |
| 18 | [2-c-11]-thymidine Pet Scan in Non-hodgkin Lymphoma | 1 |
| 19 | Cyclosporin-a Induced Hypertension in Bone-marrow Transplantation | 6 |
| 20 | The Role of the Spleen in Hemolysis | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.